Poor prognosis of intra-tumoural TRBV6-6 variants in <i>EGFR</i>-mutant NSCLC: Results from the ADJUVANT-CTONG1104 trial
Cunte Chen,Siyang Maggie Liu,Yedan Chen,Ming Han,Qiuxiang Ou,Hua Bao,Ling Xu,Yikai Zhang,Jia-Tao Zhang,Wenzhao Zhong,Qing Zhou,Xue-Ning Yang,Yang Shao,Yi-Long Wu,Si-Yang Liu,Yangqiu Li
DOI: https://doi.org/10.1002/ctm2.775
IF: 8.554
2022-01-01
Clinical and Translational Medicine
Abstract:Tumour-infiltrating lymphocytes (TILs) contain T-cell subsets, which are related to immune escape and poor clinical outcomes of cancer patients. Little is known which T-cell receptor (TCR) clones belong to such T cells. Here, we identified that Vβ6-6Jβ1-3 and Vβ6-6Jβ1-6 are associated with poor prognosis for epidermal growth factor receptor (EGFR)-mutant stage II/III non-small-cell lung cancer (NSCLC) patients treated with adjuvant gefitinib or chemotherapy VP (vinorelbine/cisplatin) in the ADJUVANT-CTONG1104 trial. EGFR tyrosine kinase inhibitor is the standard targeted therapy for EGFR-mutant NSCLC patients.1, 2 For resectable EGFR-mutant NSCLC patients, the ADJUVANT-CTONG1104 trial showed that the first generation of EGFR-TKI gefitinib could significantly improve disease-free survival (DFS) of patients with N1/N2 lymph node metastasis.3 However, there is still heterogeneity in the clinical response to EGFR-TKIs, which may be related to EGFR co-mutations or immune checkpoint expression.4, 5 Regulatory T cells are correlated with cyclooxygenase-2 expression and are closely associated with adverse clinical outcome of resected NSCLC.6 A recent study reported that TCR clone Vβ6-6 was significantly increased in exhausted T cells at baseline of NSCLC patients treated with immune checkpoint blockade.7 While factors such as quantity of T cells in TILs have been shown to be prognostic, it remains of great interest to investigate whether any specific TCR clones may be prognostic or predictive of treatment efficacy. In this study, we further characterized the TCR repertoire of patients from the ADJUVANT-CTONG1104 trial and investigated the predictive potential of specific TCR-β clones for prognosis as well as benefit from adjuvant gefitinib or chemotherapy in EGFR-mutant NSCLC patients (Figure S1). NSCLC samples from 57 gefitinib-treated patients and 44 chemotherapy-treated patients were collected for TCR β gene sequencing to obtain TCR repertoires (Figure S2 and Supporting Information Materials and Methods). A total of 356 distinct TCR rearrangements were identified.8 Notably, Vβ6-6Jβ1-3 and Vβ6-6Jβ1-6 demonstrated statistical significance in predicting poor overall survival (OS) (FDR adjusted p < .05, Figure 1A). Importantly, the combination of Vβ6-6Jβ1-3 and Vβ6-6Jβ1-6 was the best model in predicting OS (Figure 1B), which was internally validated by 100 repeated 10-fold cross-validation (Figure S3). Multivariate Cox regression analysis indicated that Vβ6-6Jβ1-3 contributed the greatest to OS prediction (p < .001) (Figure 1C). Overall, the results indicated both Vβ6-6Jβ1-3 and Vβ6-6Jβ1-6 associated with poor OS of EGFR-mutant NSCLC patients. Next, the ability of the optimal Vβ6-6Jβ1-3 and Vβ6-6Jβ1-6 TCR rearrangement combination model to predict OS or DFS was evaluated. Of note, the risk score was negatively correlated with OS and DFS (p < .001; Figure 1D, Figure S4 and Table S1). Similarly, patients with high frequency either Vβ6-6Jβ1-3 or Vβ6-6Jβ1-6 had significantly poor OS and DFS (p < .01, Figure 1E and Figure S5). Interestingly, hazard ratios from Vβ6-6Jβ1-3 and Vβ6-6Jβ1-6 individually were smaller compared to hazard ratios derived from the optimal combination model for both OS and DFS. These results not only show that specific TCR rearrangements (Vβ6-6Jβ1-3 and Vβ6-6Jβ1-6) are prognostic on their own, but the optimal model with a combination of these TCRs have the greatest predictive potential for prognosis of EGFR-mutant NSCLC patients. To confirm the clonotypes of TCRs, we explored the nucleotide (NT) and amino acid (AA) sequences of Vβ6-6Jβ1-3 and Vβ6-6Jβ1-6 in the high-frequency TCR groups. The NTs and AAs at both ends other than middle in the CDR3 region were almost conserved (Figure 2A,B). Herein, we identified the top five CDR3 motifs of Vβ6-6Jβ1-3 and Vβ6-6Jβ1-6 in the high-frequency group, which might reflect the common CDR3 sequences that contribute to the immune escape of EGFR-mutated NSCLC in this study. The top five CDR3 motifs for Vβ6-6Jβ1-3 were YSGS, YSRS, YSIS, TLPA, and YAGS. For Vβ6-6Jβ1-6, the top five CDR3 motifs were YSESD, DRDGG, YSGGG, YSREG, and PRGSP (Figure 2A,B). In addition, we used TKI-Gefitinib and Chemo-VP arms as training and validation cohorts, and the results indicated that Vβ6-6Jβ1-3 and Vβ6-6Jβ1-6 predicted poor OS and DFS for resected EGFR-mutant patients (p ≤ .05, Figure 3A–C). When patients carried high frequency of Vβ6-6Jβ1-3 or Vβ6-6Jβ1-6, the application of Vβ6-6 antibody or other treatment options should be considered. Mutant peptides produced by somatic tumour-specific mutations may create a neoepitope on cancer cells, which can be recognized by T cells. Therefore, the correlation of TCR rearrangements with genes with alteration rates greater than 20% was explored (Figure S6). Higher frequency of Vβ6-6Jβ1-3 rather than Vβ6-6Jβ1-6 was found in patients with NKX2-1 copy number (CN) gain, with marginal significance (p = .058), and they were significantly positively correlated (Cramer's V = 0.27, p = .007) (Figure 4A and Figure S7A). Furthermore, no significant relationship was found between Vβ6-6Jβ1-3 or Vβ6-6Jβ1-6 and TP53 exon 4/5 missense (p > .05, Figure S7B,C). Previously, we found NKX2-1 CN gain was significantly associated with poor prognosis of EGFR-mutant stage II/III NSCLC patients.9 NKX2-1 also serves an essential role in determining the fate of lung cancer cells and shaping the tumour immune microenvironment.10 Hence, results here appear to be consistent with previous findings, and demonstrated cross-talk between mutational and immune landscape. Compared to patients who were Vβ6-6Jβ1-3low and NKX2-1 wild type, patients with either Vβ6-6Jβ1-3high or NKX2-1 CN gain or both have a shorter OS or DFS, especially in Chemo-VP cohort (p < .05, Figure 4B and Figure S8A–C). Taken together, clonally expanded Vβ6-6Jβ1-3 and NKX2-1 CN gain may be an important biomarker for guiding adjuvant chemotherapy decisions in resectable early-stage NSCLC patients. In summary, we identified Vβ6-6Jβ1-3 and Vβ6-6Jβ1-6 in TILs, which were significantly correlated with poor prognosis in EGFR-mutant NSCLC patients in an adjuvant gefitinib or chemotherapy setting using a clinical trial cohort. To our best knowledge, this is the first study to identify specific TCR clone biomarkers related to poor clinical outcomes, as opposed to favourable outcomes. Results here are valuable for future prospective clinical trials and provide information for development of immunotherapy for EGFR-mutant stage II/III NSCLC patients. characterizing poor prognostic TCR clones from intra-tumoural T cells in EGFR-mutant stage II/III NSCLC patients; concurrent high-frequency Vβ6-6Jβ1-3 and NKX2-1 CN gain predicted poor prognosis of EGFR-mutant stage II/III NSCLC patients, especially in the adjuvant chemotherapy setting. This work was supported by grants from the National Natural Science Foundation of China (No. 82002413), Guangdong Provincial Applied Science and Technology Research & Development Program (No. 2016B020237006), China Postdoctoral Science Foundation (No. 2021M701422), and Guangdong Provincial Key Laboratory of Lung Cancer Translational Medicine (No. 2017B030314120). Yi-Long Wu discloses the following personal financial interests: Consulting and advisory services, speaking engagements of Roche, AstraZeneca, Eli Lilly, Boehringer Ingelheim, Sanofi, MSD, and BMS. The other authors have no conflict of interest. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.